31 results about "Wedelolactone" patented technology

The invention relates to a method for extracting wedelolactone from yerbadetajo herb. The method comprises the following steps of: crushing dry yerbadetajo herb, putting the crushed dry yerbadetajo herb in a supercritical fluid extraction kettle for extraction, adding alcohol liquid as an entrainer, collecting analytical liquid, extracting for 2-3 times by using n-butyl alcohol, combining extract liquor, concentrating to be 1/15-1/8 of the original volume, stirring with a little amount of polyamide resin, leading the n-butyl alcohol to be volatilized completely, adopting a dry process for polyamide chromatographic columns, eluting by using a chloroform-absolute ethyl alcohol mixed-solvent system, collecting eluent, evaporating and obtaining a product. The method has the advantages that the operation is simple, the energy consumption is less, and the prepared product is good in quality and high in content.

The invention relates to a drug application of a chemical substance wedelolactone for treatment of pulmonary fibrosis. The chemical substance wedelolactone is derived from a traditional Chinese medicine eclipta, and the structure is determined through spectral data; the wedelolactone can significantly improve the degree of model mouse lung tissue pulmonary fibrosis after intragastric administration, reduce NO (Nitrogen Oxide) and MDA (Methylene dioxyamphetamine) contents reflecting degree of lung injury, HYP (Hydroxyproline) content reflecting collagen deposition in the lung tissues, and cell factor TGF-beta 1 (Transforming Growth Factor) content causing pulmonary fibrosis, and inhibit human embryo lung fibroblast proliferation in vitro and HYP content of the human embryo lung fibroblast. In-vivo and in-vitro experiments show that wedelolactone can obviously improve bleomycin induced mouse pulmonary fibrosis, so that the wedelolactone can be taken as a novel drug for treating pulmonary fibrosis.

The invention relates to medical applications of wedelolactone and derivatives thereof, in particular to the applications in preparing medicines for treating T-cell mediated immunologic injury diseases (chronic hepatitis or autoimmune hepatitis). Traditional Chinese Medicine eclipta has a function of liver protection; wedelolactone is prepared after the active ingredient of eclipta is traced and separated, so the pharmaceutical function is proved to be produced by wedelolactone; the structure of wedelolactone is determined through the spectrum properties and physicochemical properties. Wedelolactone is provided with biological activities: high selective inhibition to ConA stimulated T lymphocyte proliferation, no inhibition to normal peripheral blood lymphocyte (NPBL), and no cytotoxicity; wedelolactone is the active ingredient of Traditional Chinese Medicine with liver protection function; the method for preparing a novel medicine from the active ingredient of eclipta, wedelolactone, has the advantages of discarding the dross and selecting the essential, clear medicinal ingredients, definite function, safety and effectiveness, controllable quality, reducing the adverse drug reaction, and can be suitable for mass production.

The invention discloses nanometer gold spherical shell photosensitive liposome, which consists of a conventional drug liposome and a nanometer gold spherical shell structure. A preparation method for the photosensitive liposome mainly comprises the following steps of first combining cysteine to a liposome surface wrapped with wedelolactone to make the surface rich in sulphydryl groups; then reducing gold chloride to obtain nanometer gold particles by virtue of a reducing agent sodium borohydride; finally mixing sulphydryl-modified liposome and the nanometer gold particles according to a certain proportion, and performing incubation under a specific condition to obtain the nanometer gold spherical shell photosensitive liposome. The preparation method can be implemented under normal temperature, normal pressure and a mild condition, a process is simple, reaction is easy to control, and the obtained liposome is regular in shape, has particle size distribution of 200 to 250nm and high light-heat conversion performance, and can be used for effectively absorbing near infrared light of 700 to 850nm.

The invention provides new use of wedelolactone and particularly relates to application of wedelolactone in preparation of medicaments or healthcare products for treating osteoporosis. Experiments show that wedelolactone is capable of obviously inhibiting proliferation of preosteoclast and inhibiting tartrate-resistant acid phosphatase activity of the preosteoclast; by inhibiting the proliferation and the differentiation of the preosteoclast, the bone loss is reduced, so that wedelolactone has anti-osteoporosis activity and can be used for preparing the medicaments or the healthcare products for treating the osteoporosis.

The invention discloses a medicine or health food for preventing or/and treating the Alzheimer's disease by a thymus pathway. The medicine or health food for preventing or/and treating the Alzheimer'sdisease by the thymus pathway is characterized in that the thymus pathway is aging, atrophy of thymus, decline in the immune function and development of the Alzheimer's disease, and fresh eclipta juice, recovery of thymus, improvement of the immune function, and interrupt or reverse of the development of the Alzheimer's disease. The drug or the health food is taken from fresh eclipta juice, the eclipta polyphenols flavones content in the fresh eclipta juice is 5.00-30.00%, the content of thiophenes is 1.00-10.00%, and the content of wedelolactone is 0.5-10.00%. According to the medicine or health food for preventing or/and treating Alzheimer's disease by the thymus pathway, the persisten inflammatory reaction is terminated during the stage when the pathogen infects the nasal cavity, oralcavity, intestinal tract and liver, the central nervous system is entered along special channels, and the occurrence of the Alzheimer's disease is prevented; and/or/ when evolving virus, or immune evasion modified toxin enters the central nervous system stage, the persistent neuritis response is terminated, the Alzheimer's disease pathological cascade reaction is interrupted, and the early-to-midAlzheimer's disease is treated.

The invention relates to an application of Chinese traditional herb monomer wedelolactone as a drug for treating ulcerative colitis. According to the application, wedelolactone is obtained from Chinese traditional herb material eclipta, and the structure of wedelolactone is determined according to spectrum data. Through intragastric administration of wedelolactone, the body weight change of a model mouse is obviously changed, the length of the colon is increased, the inflammation level of the colon is obviously hanged, the NO content reflecting the inflammation degree of the colon is reduced, the activity of myeloperoxidase (MPO) in the colon tissue is reduced, release of inflammatory factors IL-8 of Caco-2 cells excited byIL-1beta is inhibited in vitro. The results of in-vivo and in-vitro experiments show that wedelolactone under certain dosage can obviously inhibit release of the inflammatory factors of the colon tissue, so that the acute ulcerative colitis of the mouse caused by dextran sulphate sodium salt (DSS) can be obviously improved, and therefore, wedelolactone has a novel application as a drug for treating or improving ulcerative colitis.

The invention relates to a molecular traditional Chinese medicine sustained-release tablet for resisting bone mass loss and a preparation method thereof. The molecular traditional Chinese medicine sustained-release tablet comprises molecular traditional Chinese medicine ingredients and pharmaceutically allowed auxiliary material ingredients, wherein the molecular traditional Chinese medicine components comprise 1-5 parts of specnuezhenide (ligustrum lucidum), 1-5 parts of wedelolactone (eclipta prostrata), 0.5-3 parts of paeoniflorin (peony), 0.5-3 parts of psoralen (psoralea corylifolia), and 1-5 parts of diosgenin (yam) ]; and the auxiliary material ingredients comprise 10-50 parts of sodium alginate, 1-5 parts of carbomer (934) , 10-30 parts of hydroxypropyl methyl cellulose, 10-40 parts of lactose, and 1-5 parts of magnesium stearate. Based on a theory of Chinese medicine and a theory of sustained-release preparations, Chinese medicine pathological features of postmenopausal osteoporosis, and scientific compatibility, the molecular traditional Chinese medicine sustained-release tablet which is safe and reliable, high in bioavailability and significant in curative effect is developed.

The invention belongs to the field of biotechnology, and particularly relates to a research method of application of wedelolactone to preparation of lung cancer treating products. The invention researches influence of the wedelelactone on the activity, the cycles and the apoptosis of non-small cell lung cancer A549 cells as well as intervention to p-Caspase3, p53, p-STAT1 and STAT1 gene expressionof the cells, explores the anti-tumor effect of the wedelolactone on the A549 cells and the mechanism thereof, provides the research method of the application of the wedelolactone to the preparationof the lung cancer treating products, and provides a theoretical basis for future research on the non-small cell lung cancer treating mechanism of the traditional Chinese medicine. The research methodcomprise the following steps: performing cell culture, detecting the cell proliferation inhibiting rate by a CCK-8 method, detecting the cycles and the apoptosis of the cells through propidium iodideand Annexin-PI staining and detecting gene transcription and translation of the cells through RT-PCR and Western blot.

The invention relates to the field of medicines, in particular to an oral medicine composition for treating albinism. The oral medicine composition comprises medically acceptable excipients and raw materials. The raw materials include, by weight, 5-9 parts of wedelolactone and 1 part of metformin hydrochloride. The oral medicine composition has the advantages that obvious albinism treatment effects cannot be realized by the metformin hydrochloride, but albinism improving effects of the wedelolactone can be obviously improved if the metformin hydrochloride and the wedelolactone are jointly orally administered.

The invention relates to a new technology for large-scale preparation of a wedelolactone chemical reference substance. Through wedelolactone stability and preparation process streamlining optimization, a self-made large medium-pressure or pressure reduced silica gel column is employed for chromatography purification to obtain the wedelolactone chemical reference substance with purity greater than 98% in batches, and the scale is up to the 10g grade.

The invention relates to an application of wedelolactone in preparing a drug for treating idiopathic pulmonary fibrosis. By taking a mode of converting a TGF-beta1 induced human pulmonary epithelial cell A549 into a mesenchymal cell and a mode of differentiating a human embryonic lung fibroblast MRC-5 to myofibroblast as research objects, wedelolactone plays roles of inhibiting conversion of the TGF-beta1 induced human pulmonary epithelial cell A549 into the mesenchymal cell and differentiation of the human embryonic lung fibroblast MRC-5 to myofibroblast by inhibiting TGF-beta1 induced Smad and non-Smad signal channels. The wedelolactone improves the respiratory function and the survival rate of a mouse by improving pulmonary fibrosis related pathological change, reducing deposition of extracellular matrix proteins (ECM), adjusting expression of key proteins of the Smad signal channel and inhibiting accumulation of inflammatory cells, thereby playing a treatment role of inhibiting a pulmonary fibrosis pathological process induced by bleomycin.

The invention relates to a method for extracting and separating wedelolactone from herba ecliptae. The method comprises the following steps: primary extraction, secondary extraction, tandem column separation and crystallization and is characterized by grinding a raw material herba ecliptae, carrying out extraction, carrying out tandem column separation and then carrying out crystallization, thus obtaining required wedelolactone. The method for extracting wedelolactone from the raw material herba ecliptae is simple to operate, has the advantages of high product content and high recovery rate and is suitable for industrial production.

The invention discloses an application of wedelolactone in preparation of a medicine and a health care product for preventing and/or treating herpes virus infection. Experiments prove that wedelolactone has an inhibitory activity effect on herpes simplex virus infection, that is, wedelolactone has anti-HSV-1 and HSV-2 activity, and is relatively low in toxicity. Wedelolactone can significantly inhibit expression of related proteins and mRNA of HSV-1 and HSV-2, has obvious dose dependence, and has the best effect at the early stage after HSV infection, namely 2-4 h. Wedelolactone achieves the effect of blocking herpes virus infection by directly inactivating virus particles or intervening the replication process after viruses enter cells and inhibiting virus proliferation, and the wedelolactone can reduce the virus load in mouse tissues on the in-vivo animal level. Therefore, wedelolactone has the potential of being developed into a novel anti-HSV preparation of targeted virus particles.

The invention relates to a preparation method of high-purity wedelolactone. The preparation method comprises the steps of crushing the raw material eclipta, adding an industrial methanol solution by a quintuple to decuple quantity for ultrasonic extraction 2-3 times, concentrating the extract and then extracting the extract with ethyl acetate, collecting the extract, recovering a reagent and adsorbing the reagent removed extract through a silicagel column, carrying out isocratic elution by using petroleum ether and ethyl acetate in a volume ratio of 5: 1 to 50: 1, concentrating the eluate to obtain a coarse extract, next, separating through a high-speed counter current chromatograph, carrying out online monitoring with an ultraviolet detector, collecting the fraction and carrying out decompression concentration, crystallizing and drying to obtain the high-purity wedelolactone. The preparation method is simple and convenient to operate, high in recovery rate, large in separation quantity and low in pollution due to the adoption of the silicagel column for adsorption and isocratic elution with the petroleum ether and the ethyl acetate, and the obtained wedelolactone is high in purity and has excellent application prospect.

The invention belongs to the technical field of pharmacy, and discloses application of wedelolactone in preparing a drug for treating keratomycosis. The wedelolactone has a therapeutic effect on the keratomycosis in vivo and in vitro conditions. Under the in vitro conditions, the effect of the wedelolactone on IL-1beta secretion is studied by a human macrophage model stimulated by aspergillus fumigatus. Under the in vivo conditions, a C57BL/6 mouse keratomycosis model is adopted to study the effect of wedelolactone on corneal clinical scores, pathological changes, Caspase-1 signaling pathway and interleukin-1beta secretion in model mice. Furthermore, the application of the wedelolactone in combination with natamycin in preparing the drug for treating the wedelolactone is further provided.

The invention provides a compound nano graphene oxide drug carrier, which is the drug carrier is used for combining a natural anti-neoplastic extract wedelolactone and a photosensitizer indocyanine green to the surface of the nano graphene oxide through Phi-Phi stacking interaction. A preparation method of the compound nano graphene oxide drug carrier comprises the following steps: graphene oxideis processed through an ultrasonic method, the nano graphene oxide is obtained, the Phi-Phi stacking interaction is used, and wedelolactone and indocyanine green are loaded on the surface of the nanographene oxide in order. The preparation method is simple, the particle size of the nano graphene oxide is controlled at 100-200 nm, cycle time of the drug carrier in body can be prolonged, the compound nano graphene oxide drug carrier can absorb 600-900 nm near infrared, luminous energy is transformed to heat energy, photo-thermal treatment is realized, under irradiation of 808 nm near infrared,active oxygen is generated, and a purpose of photodynamic therapy is realized.